Larimar Therapeutics Receives 'Buy' Consensus from Analysts

Biotech firm's stock gets positive ratings from multiple research firms

Apr. 2, 2026 at 6:13am

Got story updates? Submit your updates here. ›

Larimar Therapeutics, Inc. (NASDAQ:LRMR) has received a consensus 'Buy' recommendation from the 10 brokerages currently covering the stock, according to MarketBeat.com. One analyst has a 'Sell' rating, while six have 'Buy' and three have 'Strong Buy' ratings. The average 12-month price target is $16.50.

Why it matters

Positive analyst sentiment and price targets suggest Wall Street sees significant upside potential in Larimar Therapeutics, a clinical-stage biotech focused on rare diseases. Strong buy-side support could help drive increased investor interest and share price appreciation for the company.

The details

The analysts' ratings come as Larimar Therapeutics prepares to report data from a Phase 2 open-label extension study of its lead candidate CTI-1601 for the treatment of Friedreich's ataxia, a rare and fatal genetic disease. Recent insider buying by a director also signals confidence in the company's prospects.

  • Larimar Therapeutics reported Q4 2025 results on March 19, 2026.
  • The company is expected to provide an update on the CTI-1601 study in the coming months.

The players

Larimar Therapeutics, Inc.

A clinical-stage biotechnology company focused on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.

James E. Flynn

A director at Larimar Therapeutics who recently acquired 5 million shares in a transaction valued at $25 million.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

What’s next

Larimar Therapeutics is expected to provide an update on the Phase 2 CTI-1601 study in the coming months, which could be a key catalyst for the stock.

The takeaway

The positive analyst sentiment and insider buying suggest Wall Street sees significant upside potential in Larimar Therapeutics as it advances its pipeline of rare disease treatments. However, investors will be closely watching the upcoming data readout on CTI-1601, which will be a critical indicator of the company's future prospects.